Search results for the GEO ID: GSE41315  |
(Click on the check boxes provided under "Select for analysis", to initiate grouping) |
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down) |
|
GSM ID | GPL ID |
Select for analysis |
Title |
Source name |
Description |
Characteristics |
GSM1014550 | GPL570 |
|
Karpas422_DMSO_day1_rep1
|
Karpas422, DMSO, day1, rep1
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014550
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014550/suppl/GSM1014550_K-4.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014551 | GPL570 |
|
Karpas422_DMSO_day1_rep2
|
Karpas422, DMSO, day1, rep2
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014551
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014551/suppl/GSM1014551_K-22.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014552 | GPL570 |
|
Karpas422_DMSO_day1_rep3
|
Karpas422, DMSO, day1, rep3
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014552
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014552/suppl/GSM1014552_K-40.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014553 | GPL570 |
|
Karpas422_EZH2i_day1_rep1
|
Karpas422, EZH2i, day1, rep1
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014553
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014553/suppl/GSM1014553_K-6.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014554 | GPL570 |
|
Karpas422_EZH2i_day1_rep2
|
Karpas422, EZH2i, day1, rep2
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014554
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014554/suppl/GSM1014554_K-24.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014555 | GPL570 |
|
Karpas422_EZH2i_day1_rep3
|
Karpas422, EZH2i, day1, rep3
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014555
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014555/suppl/GSM1014555_K-42.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014556 | GPL570 |
|
Karpas422_DMSO_day2_rep1
|
Karpas422, DMSO, day2, rep1
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014556
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014556/suppl/GSM1014556_K-7.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014557 | GPL570 |
|
Karpas422_DMSO_day2_rep2
|
Karpas422, DMSO, day2, rep2
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014557
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014557/suppl/GSM1014557_K-25.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014558 | GPL570 |
|
Karpas422_DMSO_day2_rep3
|
Karpas422, DMSO, day2, rep3
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014558
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014558/suppl/GSM1014558_K-43.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014559 | GPL570 |
|
Karpas422_EZH2i_day2_rep1
|
Karpas422, EZH2i, day2, rep1
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014559
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014559/suppl/GSM1014559_K-9.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014560 | GPL570 |
|
Karpas422_EZH2i_day2_rep2
|
Karpas422, EZH2i, day2, rep2
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014560
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014560/suppl/GSM1014560_K-27.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014561 | GPL570 |
|
Karpas422_EZH2i_day2_rep3
|
Karpas422, EZH2i, day2, rep3
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014561
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014561/suppl/GSM1014561_K-45.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014562 | GPL570 |
|
Karpas422_DMSO_day3_rep1
|
Karpas422, DMSO, day3, rep1
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014562
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014562/suppl/GSM1014562_K-10.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014563 | GPL570 |
|
Karpas422_DMSO_day3_rep2
|
Karpas422, DMSO, day3, rep2
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014563
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014563/suppl/GSM1014563_K-28.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014564 | GPL570 |
|
Karpas422_DMSO_day3_rep3
|
Karpas422, DMSO, day3, rep3
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014564
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014564/suppl/GSM1014564_K-46.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014565 | GPL570 |
|
Karpas422_EZH2i_day3_rep1
|
Karpas422, EZH2i, day3, rep1
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014565
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014565/suppl/GSM1014565_K-12.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014566 | GPL570 |
|
Karpas422_EZH2i_day3_rep2
|
Karpas422, EZH2i, day3, rep2
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014566
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014566/suppl/GSM1014566_K-30.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014567 | GPL570 |
|
Karpas422_EZH2i_day3_rep3
|
Karpas422, EZH2i, day3, rep3
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014567
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014567/suppl/GSM1014567_K-48.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014568 | GPL570 |
|
Karpas422_DMSO_day6_rep1
|
Karpas422, DMSO, day6, rep1
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014568
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014568/suppl/GSM1014568_K-13.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014569 | GPL570 |
|
Karpas422_DMSO_day6_rep2
|
Karpas422, DMSO, day6, rep2
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014569
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014569/suppl/GSM1014569_K-31.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014570 | GPL570 |
|
Karpas422_DMSO_day6_rep3
|
Karpas422, DMSO, day6, rep3
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014570
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014570/suppl/GSM1014570_K-49.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014571 | GPL570 |
|
Karpas422_EZH2i_day6_rep1
|
Karpas422, EZH2i, day6, rep1
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014571
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014571/suppl/GSM1014571_K-15.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014572 | GPL570 |
|
Karpas422_EZH2i_day6_rep2
|
Karpas422, EZH2i, day6, rep2
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014572
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014572/suppl/GSM1014572_K-33.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
GSM1014573 | GPL570 |
|
Karpas422_EZH2i_day6_rep3
|
Karpas422, EZH2i, day6, rep3
|
genotype: EZH2 Y641N
disease: DLBCL
cell line: Karpas422
|
Timecourse gene expression profiling of DLBCL cell line Karpas422 after EZH2 inhibitor treatment
|
| Sample_geo_accession | GSM1014573
| | Sample_status | Public on Oct 04 2012
| | Sample_submission_date | Oct 03 2012
| | Sample_last_update_date | Oct 09 2012
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | According to Trizol protocol
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | According to Affymetrix protocol
| | Sample_hyb_protocol | According to Affymetrix protocol
| | Sample_scan_protocol | According to Affymetrix protocol
| | Sample_data_processing | The gene expression data was normalized using the Robust Multiarray Averaging (RMA) method and log2 transformed before comparisons using R 2.10.1. The EZH2 inhibitor-treated cells were then compared to their corresponding DMSO-treated control groups to obtain the significantly differentially expressed gene lists using two-tailed student t test at each time point.
| | Sample_platform_id | GPL570
| | Sample_contact_name | Shannon,,Chuai
| | Sample_contact_email | shannon.chuai@novartis.com
| | Sample_contact_institute | Novartis
| | Sample_contact_address | Building 8, Lane 898 Halei Road, Pudong New Aera
| | Sample_contact_city | Shanghai
| | Sample_contact_state | Shanghai
| | Sample_contact_zip/postal_code | 201203
| | Sample_contact_country | China
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1014nnn/GSM1014573/suppl/GSM1014573_K-51.CEL.gz
| | Sample_series_id | GSE41315
| | Sample_data_row_count | 54613
| | |
|
| |
| |
Make groups for comparisons |
(2 groups will be compared at a time) |
|
| Select GSMs and click on "Add groups" |
Enter the group name here: |
|
|
|
